Bio-Techne Unveils Three‑Brand Portfolio to Simplify Scientist Workflow from Discovery to Diagnostics

Bio-Techne has restructured its product lines into three distinct brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics. This move aims to streamline workflows for scientists, guiding them from initial discovery through to clinical diagnostics.

Bio-Techne, a global supplier of life science research tools and diagnostics, introduced a new brand architecture this week. This restructuring organizes its extensive product offerings to better align with the natural progression of scientific research and clinical applications.

The company's portfolio now operates under three focused brands, each aligned with a stage of scientific progression. R&D Systems targets early-stage scientific discovery, providing foundational tools such as high-quality proteins, antibodies, immunoassays, and small molecules for reliable experimental validation. Bio-Techne Spatial then focuses on translational research, leveraging advanced technologies like RNAscope in situ hybridization and the COMET spatial hyperplex platform. These tools enable high-resolution visualization of RNA and protein, aiding in the identification of clinically relevant biomarkers. The final brand, Bio-Techne Diagnostics, supports clinical laboratories and in vitro diagnostic (IVD) manufacturers. This brand offers assay kits, IVD-grade reagents, and molecular controls necessary for developing and validating reliable diagnostic tests from early design through large-scale deployment. This alignment seeks to simplify the path for scientists as they move from initial laboratory discovery to patient diagnostics.

This strategic reorganization aims to empower scientists and clinicians, helping them obtain better answers and accelerate scientific progress. Bio-Techne states the new structure makes it easier for customers to access relevant solutions at each stage of their work. The company will showcase this updated brand structure at the AACR Annual Meeting in San Diego and IMMUNOLOGY2026 in Boston.

The scientific community will observe how this streamlined approach impacts research efficiency and accelerates new therapeutic and diagnostic developments.